← Back to Clinical Trials
Recruiting NCT05443906

NCT05443906 Home Exercise for Individuals with Neurodegenerative Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05443906
Status Recruiting
Phase
Sponsor Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Condition Neurodegenerative Diseases
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2023-02-13
Primary Completion 2026-07-30

Eligibility & Interventions

Sex All sexes
Min Age 5 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Home exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2023-02-13 with a primary completion date of 2026-07-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary goal of this study is to address the need for targeted therapeutic interventions for impairments that impact walking in related neurodegenerative diseases.

Eligibility Criteria

Inclusion Criteria: * The eligibility criteria for males is X-linked adrenoleukodystrophy as determined by biochemical determination or genetic testing. * The eligibility criteria for females is X-linked adrenoleukodystrophy as determined by biochemical determination, genetic testing, or pedigree analysis. * The Leukoenceophalopathy with brainstem and spinal cord involvement and lactate elevation inclusion criterion is a confirmed DARS2 mutation through genetic analysis. * For people with cerebellar ataxia, people with diagnoses of cerebellar damage from stroke, tumor or degeneration will be included. Those with a genetically confirmed cerebellar disorder will be asked to provide their genetic testing to note their particular type of ataxia. * We will also include patients with other neurodegenerative diseases similar to these disorders as determined by chart review and clinical exam. Healthy Volunteers * Able to stand for 30 seconds without upper extremity support * Ambulatory (including use of a cane or a walker) * Able to walk for 2 minutes Exclusion Criteria: * Other medical or psychological conditions which in the clinical judgement of the investigator would interfere with acquiring the study information or performing the exercises safely including but not limited to: Uncontrolled hypertension, orthopedic conditions, diabetes, seizure disorder, peripheral vestibular loss, severe aphasia, dementia, pregnancy

Contact & Investigator

Central Contact

Jennifer L Keller, PT, MS

✉ keller@kennedykrieger.org

📞 443-923-2716

Principal Investigator

Jennifer Keller, PT

PRINCIPAL INVESTIGATOR

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Frequently Asked Questions

Who can join the NCT05443906 clinical trial?

This trial is open to participants of all sexes, aged 5 Years or older, up to 75 Years, studying Neurodegenerative Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05443906 currently recruiting?

Yes, NCT05443906 is actively recruiting participants. Contact the research team at keller@kennedykrieger.org for enrollment information.

Where is the NCT05443906 trial being conducted?

This trial is being conducted at Baltimore, United States.

Who is sponsoring the NCT05443906 clinical trial?

NCT05443906 is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, Inc.. The principal investigator is Jennifer Keller, PT at Hugo W. Moser Research Institute at Kennedy Krieger, Inc.. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology